Title: Director, Commercialization Practice
Category: Managing Professional
Education: B.A., MBA Finance, PhD Economics
Mr. Kleckner has served for over 20 years as an advisor, board member, founding CEO and chief business development officer for emerging life science and information system ventures and not-for-profit [501 (c) 3] organizations. He has been a management consulting expert to 46 corporations and 23 healthcare systems throughout Europe, Asia and the Americas. He was co-founder and CEO for U P Laboratories developing peptides that mimic the behavior of botulinum neurotoxin (BoTox©), Senior Vice President, Business Development for and Investor in InSilicoMed in commercializing a bioengineering software for simulation of the human heart and how it prospectively reacts to heart failure therapies, SVP Business Development and Investor in RegeneMed for engineered human liver tissue for new drug discovery applications, Chief Business Officer for SEATreat specializing in precursor cervical, ovarian, oral and pharyngeal cancer diagnostics, and Co-Founder, Chief Business Officer for Salvino-Flex developing a chest tube insertion device for pulmonary thoracic trauma. Mr. Kleckner has also been a lead healthcare economist for Roche Diagnostics, Roche (Mannheim), Terumo Interventional, Respironics (Philips Medical), Toshiba Medical, and VapoTherm.
He also gives back as business advisor and lead fund raiser for the Nicholas Conor Institute (patient and cancer - genome specific pediatric cancer therapies) and is a contributing partner for raising funds on behalf of the Social Venture Partners for at risk children, families in need, the elimination of hunger and homelessness, the environment and education. His hybrid venture philanthropy initiative is being publicized in the Wall Street Journal and as a front page three-part series in the San Diego Business Journal. He developed the TACTiC™ research collaboration for small niche markets to motivate capital investments and is leading a comprehensive study with Price Waterhouse Cooper on the prospective economic and clinical blended impact of personalized medicine in pediatric oncology. Mr. Kleckner teaches graduate school at the University of California, Riverside and California State University, San Marcos Masters in Biotechnology programs. He also serves as teacher and mentor for the Young Entrepreneurs Project, Economic and Work Force Development Program at regional high schools and community colleges - through the Small Business Development Corporation's (SBDC) program for entrepreneurial initiatives on small business funding, business development, management and sustainability.
He has an MBA (Finance) from the University of California, Los Angeles (UCLA Anderson School) , a PhD (Economics/Public Policy) from University of California, Riverside , a Certificate in Public Health from University of California, San Diego, and a bachelors degree from Whittier College.